JustHealth Technologies: Building an AI-Powered Post-Visit Healthcare Ecosystem with Follow-Up as the Gateway

Follow-up is a component of the healthcare system that evokes mixed feelings among physicians.

Love it, as it not only bridges the gap between doctors and patients and improves healthcare quality, but also helps physicians collect relevant clinical data for scientific research; hate it, because assigning scarce physician resources to manage a massive patient population is undeniably challenging, with follow-up often meaning “more work without additional compensation” for doctors. Having the will but lacking the capacity is a common plight among medical professionals in China when dealing with patient follow-up.

Why has this situation arisen? Wang Jian, CEO of Jianhai Technology, stated in an interview with a reporter from VCBeat: “A physician’s primary duty and value lie in diagnosis and treatment, whereas establishing long-term connections with patients is inherently a service-oriented endeavor.”

In his view, the follow-up care market is a vast blue ocean. The biggest pain point in this market is the shortage of time among healthcare professionals, which prevents the existing medical system from supporting the rapid development of the follow-up care market. Therefore, innovation is needed in this industry.

Wang Jian, CEO of Jianhai Technology (Image provided by the interviewee)

The core team members of Jianhai Technology hail from renowned enterprises such as SinoCare, Insigma, Alibaba, and Lianzhong. Established in 2015, this life sciences company focuses primarily on post-discharge patient management. Guided by the philosophy of “making care a potent remedy,” it leverages an integrated model of Internet, IoT, and AI to extensively interface with hospital HIS systems, facilitating refined management of the closed-loop journey from hospital discharge to home care and subsequent follow-up visits.

Over the past four years since its launch, Jianhai Technology has established in-depth collaborations with more than 200 hospitals, including over 20 of China’s Top 100 hospitals and approximately 60% Grade-A tertiary hospitals. The company has served more than 20 million inpatients and nearly 100 million patient visits, and has facilitated the completion of nearly 100 scientific research papers, including publications in Cell and projects under the National High-Tech R&D Program (863 Program).

Under the current healthcare system, there are two primary modes of medical care: proactive care and reactive care. Follow-up is a component of proactive care, requiring physicians to actively monitor patients’ conditions. However, this raises a critical issue: given the severe scarcity of medical resources in China, where even basic treatment for patients cannot be guaranteed, how can healthcare providers allocate the necessary energy and resources to conduct patient follow-ups?

Many patients, especially those with chronic diseases, can only complete the medical consultation process in hospitals, while most rehabilitation and recuperation need to be carried out at home. Therefore, follow-up care does not merely mean a simple inquiry but requires establishing long-term contact with patients. In Wang Jian's view, separating medical consultations from services is key to freeing up doctors, allowing them more time to focus on their core responsibilities.

This is Wang Jian’s original aspiration in establishing Jianhai Technology: to manage health data through artificial intelligence, thereby enabling proactive treatment under an AI-driven framework.

During the entrepreneurial journey, Wang Jian observed that many companies in the industry, which initially focused on patient follow-up as their core business, struggled to sustain growth in their mid-to-late stages and pivoted toward online consultation services. Therefore, he sought to identify the correct approach to unlocking this market. “If the consultation market is likened to the ‘gatekeeper’ of health, then patient follow-up serves as the ‘back garden’ of health. However, having a small group of physicians manage a vast population of patients would certainly not provide a satisfactory experience for patients in this ‘back garden.’”

Therefore, traditional innovations centered on service models have yielded limited results. Regardless of how enterprises design follow-up software for hospitals, shifting medical resources from offline to online settings within constrained time and energy cannot fundamentally resolve the issue of healthcare operational efficiency. Without establishing a systematic healthcare service framework, the follow-up care market cannot be truly revitalized.

“Artificial intelligence technology is poised to break through this constraint; fundamental tasks such as follow-up reminders can be handled by AI agents, which underscores the true value of artificial intelligence.”

To systematize the follow-up process, two issues must first be addressed: first, establishing an informational closed loop for patient consultations and rehabilitation; second, addressing patient screening and batch follow-ups.

Jianhai Technology starts with software, links patients' electronic medical records, and manages patients' diseases through "cloud follow-up". Its main features are as follows:

I. Extensive Integration with Hospital HIS and Electronic Medical Record Systems. The Hospital Information System (HIS) is the core infrastructure of a hospital, storing vast amounts of critical patient data. Integrating with the hospital’s HIS enables follow-up physicians to flexibly access patients’ diagnostic and treatment information anytime and anywhere. The ability to integrate with hospital HIS is one of the key benchmarks for assessing the core competitiveness of healthcare IT companies in the market. As a post-discharge disease management platform, the cloud-based follow-up system complements care by tracking medication adherence, rehabilitation status, and clinical symptoms after patients leave the hospital. Achieving integration between these two systems establishes an informational closed loop covering both in-hospital diagnosis and treatment and out-of-hospital rehabilitation.

II. AI Technology for Disease Management Based on Knowledge Graphs. The underlying technical support for Cloud Follow-up is derived from “Jishi,” a disease management AI independently developed by Jianhai Technology. Built on advanced big data infrastructure, the Jishi system has learned from follow-up process data covering over 3,000 diseases and incorporates experience accumulated by more than 50 chronic disease management and operations teams. By leveraging deep learning techniques with fused neural network algorithms, it enables batch patient follow-ups through various interaction channels, including WeChat, telephone, smart speakers, and robots. During the follow-up process, the system provides intelligent auxiliary functions such as automated judgment of anomalies in follow-ups, test results, and patient feedback, as well as automated responses and reminders.

After doctors import patient information into the Jishi system, the AI first deconstructs the clinical condition to analyze potential issues, such as the presence of complications or the need for specialized medications. Based on this analysis, it then designs tailored questioning strategies to assess the patient’s condition. Furthermore, Jishi AI possesses superior conversational learning capabilities compared to general staff and can communicate with patients using realistic synthetic voice technology, thereby eliminating communication barriers.

Wang Jian told VCBeat, “Data and AI are not simply combined; rather, they jointly serve as a physician’s assistant, addressing the lack of systematic follow-up previously caused by physicians’ limited time. This substantial reduction and simplification of workload provide physicians with the incentive to oversee patient follow-up.”

In addition to selling AI systems to hospitals, Jianhai Technology is also attempting to build a third-party disease management platform by spinning off hospital follow-up services and having its own in-house team manage patients’ diseases on behalf of the hospitals.

Wang Jian stated that once third-party platforms standardize and systematize follow-up services, in addition to freeing up physicians’ time and providing better services to patients, another significant benefit is that follow-up services can be developed into standalone products, no longer constrained by limitations in human and material resources.

In actual clinical practice, not all patients require follow-up. How can we ensure accurate tracking of the recovery progress for patients who do need follow-up while conserving resources as much as possible? To address this, Jianhai Medical has proposed the concept of a “follow-up prescription.” Specifically, during outpatient consultations, physicians, based on the complexity of the patient’s condition and their prognosis for recovery, prescribe follow-up as a standalone service product for patients with follow-up needs, incorporating it directly into their prescriptions.

Thus, on the one hand, hospitals are spared the need for patient market education; on the other hand, upon receiving a prescription, third-party service platforms can conduct timely and targeted follow-up of the patient’s condition.

“Under this model, patients are no longer in a passive position; with adequate mental preparation, they can proactively record their rehabilitation status and submit feedback to third-party service platforms. These platforms then relay the patients’ rehabilitation information back to physicians through the Hospital Information System (HIS). This approach not only establishes a closed loop for collecting clinical and rehabilitation data but also enables rapid and efficient circulation of patient information within the healthcare system,” said Wang Jian.

In the future, the models of assisting hospital follow-ups and third-party disease management will advance side by side, jointly driving the development of Jianhai Technology. To this end, Jianhai Technology must also strengthen its R&D in AI technology and devote more resources to market expansion.

Currently, Hangzhou Jianhai Science and Technology Co., Ltd. is seeking Series A+ financing, with Tan Zhen Capital serving as the exclusive financial advisor for this round.